B of A Securities Maintains Buy on 4D Molecular Therapeutics, Raises Price Target to $33
B of A Securities analyst Tazeen Ahmad maintains 4D Molecular Therapeutics (NASDAQ:FDMT) with a Buy and raises the price target from $29 to $33.
Share
Why It Matters
A big bank analyst thinks 4D Molecular is a good stock to own. They raised their price target, meaning they see more future promise in the company.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.